Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep upregulates PD-(L)1 / PD-L2

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 30, 2024 1:41pm

82 Views

Post# 36289123

RE:RE:ONCY's pelareorep upregulates PD-(L)1 / PD-L2

Also - upregulated levels of PD-L1 (High-PD-L1) are associated with high levels of tumor infilitrating lymphocytes (TiLs) and stem cell markers which in turm serve to remodel an immunosupressive TME found surrounding cancer cells, and which contributes to a cancer cell's growth and spread.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario